Business Wire

Talkdesk Enters Next Decade Fueled by Innovation, Expanded International Presence, New Brand

27.4.2021 18:30:00 EEST | Business Wire | Press release

Share

Talkdesk®, Inc., the global customer experience leader for customer-obsessed companies, today embarked on the next phase of growth after two years of significant momentum in executing toward its bold vision to provide a better way for organizations to unlock the promise and potential of great customer service. To mark this new stage in its corporate maturation, Talkdesk unveiled a new logo and tagline – Experience. A better way. – that reflects the company’s commitment to being at the forefront of customer experience (CX) innovation and its focus on empowering customers to build brand trust and loyalty through customized, personal interactions.

Talkdesk’s reimagined logo reflects its commitment to helping companies connect every engagement moment into customer journeys that are personalized, productive and profitable. The bold new corporate identity comprises a fresh purple color palette and updated brand elements, featuring inclusive and diverse visual representations and illustrations that reflect the importance of human connection. The company also relaunched its website in five new languages – Brazilian Portuguese, French, German, Portuguese and Spanish, and unveiled a powerful new international advertising campaign.

“Today is about retelling the Talkdesk story in a way that pays tribute to our legacy, embraces our commitment to diversity and giving back, and deeply connects our path forward to the thousands of Talkdesk customers and employees who made what is yet to come possible,” said Kathie Johnson, chief marketing officer, Talkdesk. “Every element of who we are represents the importance of the connection we help companies make with their customers, because every moment matters.”

Talkdesk today also introduced availability of two additions to Talkdesk CX Cloud™ designed to propel the company into its new wave of growth: Talkdesk Workspace, a customizable user interface, and Talkdesk Builder, a set of tools for unlimited and accelerated contact center customization across workspaces, routing, reporting and integrations. Since its inception, rapid innovation has been a Talkdesk hallmark – one applauded by both customers and industry leaders, and valued by enterprise customers worldwide.

“Ten years ago, Talkdesk founder Tiago Paiva saw how Salesforce had re-invented the CRM world and realized a similar revolution was imminent for the call center,” said Sheila McGee-Smith, founder and principal analyst, McGee-Smith Analytics, LLC. “Talkdesk has been a significant part of the industry-wide contact center transformation, helping to move the industry toward a true elastic cloud, with all the innovation power that brings for not just customers but the entire customer experience ecosystem.”

Over the past 24 months, Talkdesk achieved several significant milestones, including:

  • An international expansion that extended the company’s footprint not only within Portugal, the United Kingdom and the United States, but also into Australia, Brazil, France, Germany, Ireland, Italy, the Netherlands, Southeast Asia and Spain
  • A proven executive leadership team – which is 45% female – with experience at some of the technology industry’s leading companies, including AT&T, Cloudera, Oracle, Salesforce and SAP
  • Bringing to market 20 innovations in the first 20 weeks of 2020, including solutions designed to help its customers through the pandemic
  • Expansion and strengthening of its partner ecosystem of cloud distributors, resellers, marketplace and strategic alliance partners
  • Launching industry specific solutions to help address the unique customer service challenges of financial services and insurance, healthcare and life sciences, retail and e-commerce, and travel and hospitality companies
  • Raising Series C funding of $143 million, bringing the company’s valuation to more than $3 billion
  • Positioned as a leader in the 2020 Gartner Cloud Contact Center as a Service (CCaaS) Magic Quadrant
  • Positioned as a leader in the 2020 Forrester Wave for CCaaS

“Today marks an inflection point in Talkdesk history. Talkdesk was founded on the principle that there had to be a better way for companies to deliver exceptional customer service. We now have customers in every major region of the world who have transformed their end-customers’ experience into an immersive, personalized and profitable journey,” said Tiago Paiva, Talkdesk founder and chief executive officer. “Our cloud-native platform was one of many industry-firsts Talkdesk introduced to the contact center marketplace over its first decade, and our talented

development team is hard at work on the products that will define our next 10 years of audacious innovation.”

Additional Resources

  • Read Kathie Johnson’s perspective on leading Talkdesk through transformation growth as the company’s first chief marketing officer
  • Read the press release introducing Talkdesk Workspace, a customizable interface designed to enable a better way to deliver superior customer experiences in contact centers
  • Learn more about the new Talkdesk brand

Social Networks

About Talkdesk

Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of the does not imply any affiliation or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Americas
Camille Beasley
camille.beasley@talkdesk.com
(972) 896-1936

EMEA
Douglas Keighley
douglas.keighley@talkdesk.com
+44 7830144613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye